Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 13, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

704

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

M Sahay1, Y Saivani1, K Ismal1

  • 1Department of Nephrology, Osmania General Hospital, Hyderabad, Telangana, India.

Indian Journal of Nephrology
|March 9, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker Combination Therapy With Reference to Telmisartan and Cilnidipine.

Cureus·2026
Same author

The changing landscape in nephrology education in India.

Frontiers in nephrology·2023
Same author

Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

P300 as a marker of cognitive dysfunction in chronic epileptics.

Neurology India·2018
Same author

An unusual case of nephrotic syndrome.

Indian journal of nephrology·2016
Same author

Splenorenal graft: A safe and effective treatment for renovascular hypertension.

Indian journal of nephrology·2015

Cyclophosphamide (CPM)-based regimens offer a safe, effective, and cost-efficient alternative to mycophenolate mofetil (MMF) for treating lupus nephritis, even in resource-limited settings.

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Background:

  • Systemic lupus erythematosus (SLE) frequently causes chronic kidney disease, particularly lupus nephritis.
  • Renal involvement in SLE significantly impacts patient prognosis and necessitates effective treatment strategies.

Purpose of the Study:

  • To compare the efficacy and safety of cyclophosphamide (CPM)-based regimens (low and high dose) against mycophenolate mofetil (MMF)-based regimens for lupus nephritis.
  • To evaluate CPM as a cost-effective alternative to MMF in resource-limited settings.

Main Methods:

  • A comparative study involving 144 patients with lupus nephritis.
  • Assessment of treatment outcomes including remission rates, end-stage renal disease, and adverse events.
  • Analysis of treatment costs associated with different immunosuppressive regimens.
Keywords:
Cyclophosphamideinductionlupus nephritismycophenolatesystemic lupus erythematoustreatment

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.7K
Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.6K

Related Experiment Videos

Last Updated: Feb 13, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

704
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.7K
Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method
05:28

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

2.6K

Main Results:

  • Overall remission rates at 6 months were comparable across the National Institute of Health (NIH) regimen (71.4%), European Lupus Nephritis Trial (ELNT) protocol (65%), and MMF regimen (72.9%).
  • End-stage renal disease incidence and need for therapy switching were similar among the groups.
  • CPM-based therapies demonstrated significantly lower costs, despite a non-statistically significant trend towards more infections.

Conclusions:

  • CPM-based regimens are a viable, cost-effective, and safe alternative to MMF for lupus nephritis treatment, especially in resource-limited environments.
  • Treatment efficacy and safety profiles are comparable across CPM and MMF regimens, supporting their use in managing lupus nephritis.